Centrum 7/6  banner

Nimble Therapeutics

Nimble teams to discover and develop novel peptide-based compounds for SARS-CoV-2 diagnostics

Nimble teams to discover and develop novel peptide-based compounds for SARS-CoV-2 diagnostics

MADISON, Wis. — Nimble Therapeutics announced a collaboration with Roche Diagnostics to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro diagnostic assays. Nimble will extend its proprietary peptide synthesis, screening and optimization platform to enable faster discovery and optimization of promising compounds for detecting SARS-CoV-2. Roche will leverage its world-class

Nimble announces collaboration with Genentech

Nimble announces collaboration with Genentech

MADISON, Wis. — Nimble Therapeutics announced a multi-year collaboration with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases.   The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable

PP_1170x120_10-25-21